Background Each year, worldwide, about 3 million people die as a result of trauma, many
after reaching hospital. Among trauma patients who do survive to reach hospital, bleeding is …

BACKGROUND: The aim of the CRASH-2 trial was to assess the effects of early
administration of tranexamic acid on death, vascular occlusive events, and blood transfusion …

Background The CRASH-2 trial showed that early administration of tranexamic acid (TXA)
safely reduces mortality in bleeding in trauma patients. Based on data from the CRASH-2 …

Background Women are less likely than men to receive some emergency treatments. This
study examines whether the effect of tranexamic acid (TXA) on mortality in trauma patients …

Objectives To examine whether the effect of tranexamic acid on the risk of death and
thrombotic events in patients with traumatic bleeding varies according to baseline risk of …

This important paper addressed a key clinical question, which was exceptionally novel at the
time of investigation. Namely, could the early administration of 1 gram of tranexamic acid …

Objective: To characterize the relationship between tranexamic acid (TXA) use and patient
outcomes in a severely injured civilian cohort, and to determine any differential effect …

Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine that inhibits
fibrinolysis by blocking the interaction of plasminogen with the lysine residues of fibrin …

Objective To assess the cost effectiveness of giving tranexamic acid (TXA) to bleeding
trauma patients in low, middle and high income settings. Methods The CRASH-2 trial …

Tranexamic acid (TXA) reduces blood loss by inhibiting the enzymatic breakdown of fibrin. It
is often used in surgery to decrease bleeding and the need for blood transfusion. In 2011 …